JP2022500417A5 - - Google Patents
Info
- Publication number
- JP2022500417A5 JP2022500417A5 JP2021513947A JP2021513947A JP2022500417A5 JP 2022500417 A5 JP2022500417 A5 JP 2022500417A5 JP 2021513947 A JP2021513947 A JP 2021513947A JP 2021513947 A JP2021513947 A JP 2021513947A JP 2022500417 A5 JP2022500417 A5 JP 2022500417A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- masseter muscle
- botulinum toxin
- width
- administer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024154914A JP2024177185A (ja) | 2018-09-13 | 2024-09-09 | 咬筋肥大症の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731064P | 2018-09-13 | 2018-09-13 | |
| US62/731,064 | 2018-09-13 | ||
| PCT/US2019/050910 WO2020056204A1 (en) | 2018-09-13 | 2019-09-12 | Methods for treatment of masseter muscle hypertrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024154914A Division JP2024177185A (ja) | 2018-09-13 | 2024-09-09 | 咬筋肥大症の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022500417A JP2022500417A (ja) | 2022-01-04 |
| JP2022500417A5 true JP2022500417A5 (https=) | 2022-09-21 |
Family
ID=68069888
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513947A Pending JP2022500417A (ja) | 2018-09-13 | 2019-09-12 | 咬筋肥大症の治療方法 |
| JP2024154914A Pending JP2024177185A (ja) | 2018-09-13 | 2024-09-09 | 咬筋肥大症の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024154914A Pending JP2024177185A (ja) | 2018-09-13 | 2024-09-09 | 咬筋肥大症の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20200085923A1 (https=) |
| EP (1) | EP3849585A1 (https=) |
| JP (2) | JP2022500417A (https=) |
| KR (1) | KR20210057106A (https=) |
| CN (1) | CN112955166A (https=) |
| AU (2) | AU2019337656A1 (https=) |
| BR (1) | BR112021004776A2 (https=) |
| CA (1) | CA3112227A1 (https=) |
| MX (1) | MX2021002993A (https=) |
| TW (2) | TW202434280A (https=) |
| WO (1) | WO2020056204A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230152107A (ko) * | 2021-02-26 | 2023-11-02 | 이온 바이오파마, 인크. | 두통을 치료하는 데 사용하기 위한 신경독소 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| US6423319B1 (en) * | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
| CA2501856A1 (en) * | 2002-10-15 | 2004-04-29 | Allergan, Inc. | Botulinum toxin dental therapies and procedures |
| US20060057165A1 (en) * | 2004-09-10 | 2006-03-16 | Dimitrios Dimitrakoudis | Clostridium botulinum toxin formulation and method for reducing weight |
| WO2006073410A1 (en) * | 2005-01-03 | 2006-07-13 | Botulinum Toxin Research Associates, Inc. | Compositions, methods and devices for preparing less painful botulinum toxin formulations |
| WO2009139739A1 (en) * | 2006-02-14 | 2009-11-19 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion |
| US20080021437A1 (en) * | 2006-04-27 | 2008-01-24 | Boyd James P | Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A |
| RU2535115C1 (ru) * | 2013-05-15 | 2014-12-10 | Бости Трейдинг Лтд | Фармацевтический состав, содержащий нейротоксин ботулина |
| US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| EP3368071B1 (en) * | 2015-10-29 | 2022-01-26 | ReVance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
-
2019
- 2019-09-12 CN CN201980069678.6A patent/CN112955166A/zh active Pending
- 2019-09-12 KR KR1020217010431A patent/KR20210057106A/ko active Pending
- 2019-09-12 CA CA3112227A patent/CA3112227A1/en active Pending
- 2019-09-12 WO PCT/US2019/050910 patent/WO2020056204A1/en not_active Ceased
- 2019-09-12 EP EP19778736.9A patent/EP3849585A1/en active Pending
- 2019-09-12 AU AU2019337656A patent/AU2019337656A1/en not_active Abandoned
- 2019-09-12 MX MX2021002993A patent/MX2021002993A/es unknown
- 2019-09-12 BR BR112021004776A patent/BR112021004776A2/pt unknown
- 2019-09-12 JP JP2021513947A patent/JP2022500417A/ja active Pending
- 2019-09-13 US US16/570,232 patent/US20200085923A1/en not_active Abandoned
- 2019-09-16 TW TW112144521A patent/TW202434280A/zh unknown
- 2019-09-16 TW TW108133293A patent/TWI835858B/zh active
-
2022
- 2022-05-30 US US17/804,577 patent/US20230083250A1/en not_active Abandoned
- 2022-05-30 US US17/804,575 patent/US20230080740A1/en not_active Abandoned
-
2024
- 2024-09-09 JP JP2024154914A patent/JP2024177185A/ja active Pending
-
2025
- 2025-09-03 AU AU2025226702A patent/AU2025226702A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021192835A5 (https=) | ||
| NZ700623A (en) | Botulinum toxin dosage regimen for chronic migraine prophylaxis | |
| EP4470595A3 (en) | Delivery of botulinum with microneedle arrays | |
| ZA202107358B (en) | Method for treating alzheimer's disease | |
| MY179696A (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| WO2017097723A3 (en) | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies | |
| ATE531387T1 (de) | Nahtlinien-verabreichungstechnik mit botulinustoxinen | |
| EP4523756A3 (en) | Immunotherapeutic vaccine and antibody combination therapy | |
| JP2021504412A5 (https=) | ||
| WO2017172771A3 (en) | Treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody | |
| MX2014004548A (es) | Metodos para tratar pacientes pediatricos usando dexmedetomidina. | |
| WO2007124461A3 (en) | Glp-1 compounds | |
| WO2015033319A3 (en) | Apparatus and methods for diagnosis and treatment of patterns of nervous system activity affecting disease | |
| MY153062A (en) | Methods of treating gastrointestinal disorders independent of the intake of food | |
| MX2020009265A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23. | |
| PH12020552088A1 (en) | Vmat2 inhibitor compounds, compositions, and methods relating thereto | |
| JP2016519107A5 (https=) | ||
| JP2015522522A5 (https=) | ||
| PH12020551159A1 (en) | Methods of treating subjects having diabetes with chronic kidney disease | |
| FI3445351T3 (fi) | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen | |
| JP2022500417A5 (https=) | ||
| MX2020005438A (es) | Formas de dosificacion de sulfato de morfina disuasivas del abuso. | |
| MX2024005197A (es) | Métodos para tratar la enfermedad de crohn con el anticuerpo específico anti-il23. | |
| EP4461356A3 (en) | Methods of treating an ischemic disease | |
| WO2015200052A3 (en) | System and method for acclimating a new user to a breathing therapy machine |